Literature DB >> 21187364

Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

F Croce1, P Vitello, A Dalla Pria, A Riva, M Galli, S Antinori.   

Abstract

Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21187364     DOI： 10.1258/ijsa.2010.010246

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN： 0956-4624            Impact factor:   1.359


  9 in total

1.  Management of Antiretrovirals in Critically Ill Patients: Great Progress But Potential Pitfalls.

Authors:  Dante A Suffredini; Jomy M George; Henry Masur
Journal:  Crit Care Med       Date:  2018-05       Impact factor: 7.598

2.  Role of raltegravir in the management of HIV-1 infection.

Authors:  N Lance Okeke; Charles Hicks
Journal:  HIV AIDS (Auckl)       Date:  2011-07-15

3.  Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis.

Authors:  Sylvain Raoul Simeni Njonnou; Sophie Henrard; Lamya Noure; Jean-Christophe Goffard
Journal:  BMJ Case Rep       Date:  2020-07-01

Review 4.  Long-term efficacy and safety of raltegravir in the management of HIV infection.

Authors:  Michelle D Liedtke; C Ryan Tomlin; Staci M Lockhart; Misty M Miller; R Chris Rathbun
Journal:  Infect Drug Resist       Date:  2014-03-18       Impact factor: 4.003

5.  Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy.

Authors:  Guan-Jhou Chen; Hsin-Yun Sun; Aristine Cheng; Yu-Chung Chuang; Yu-Shan Huang; Kuan-Yin Lin; Yi-Chia Huang; Wen-Chun Liu; Pei-Ying Wu; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.

Authors:  Muhammad Saad; Fernando Casado-Castillo; Paul Kelly
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  A suspected case of hyponatraemia induced rhabdomyolysis: a case report.

Authors:  Edward Reakes; Douglas Drak; David Gracey
Journal:  BMC Nephrol       Date:  2022-05-11       Impact factor: 2.585

Review 8.  HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.

Authors:  Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

9.  A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.

Authors:  Veronique Suttels; Eric Florence; John Leys; Marc Vekemans; Jef Van den Ende; Erika Vlieghe; Chris Kenyon
Journal:  J Med Case Rep       Date:  2015-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.